CTC
LGND icon

Cetera Trust Company’s Ligand Pharmaceuticals LGND Stock Holding History

Cetera Trust Company’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$575K Hold
2,880
– – 0.33% 62
2025
Q4 		$545K Hold
2,880
– – 0.29% 65
2025
Q3 		$510K Hold
2,880
– – 0.29% 68
2025
Q2 		$327K Buy
2,880
+225
+8% +$24K 0.2% 92
2025
Q1 		$279K Hold
2,655
– – 0.18% 109
2024
Q4 		$284K Buy
2,655
+75
+3% +$8.48K 0.18% 99
2024
Q3 		$258K Buy
2,580
+25
+1% +$2.52K 0.16% 131
2024
Q2 		$215K Buy
2,555
+75
+3% +$5.97K 0.14% 144
2024
Q1 		$181K Buy
2,480
+275
+12% +$20.3K 0.11% 176
2023
Q4 		$157K Buy
+2,205
New +$130K 0.1% 174

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Cetera Trust Company's LGND Position: Q1 2026 in Review

Cetera Trust Company held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 2,880 shares worth $575K. The position accounts for 0.33% of the portfolio, ranked #62.

Cetera Trust Company first reported a position in LGND in Q4 2023 and has held it in 10 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Cetera Trust Company held 2,880 shares of Ligand Pharmaceuticals worth $575K as of Q1 2026.
  • Cetera Trust Company left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up 0.33% of Cetera Trust Company's portfolio in Q1 2026, its #62 holding.
  • Cetera Trust Company first reported a position in Ligand Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Cetera Trust Company's 13F filing for Q1 2026, filed 8 May 2026.